Vincerx Pharma Files 8-K, Reports Material Agreement
Ticker: VINC · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $13.66 m, $13.66 million, $1,500,000, $1,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, company-name-change, filing
TL;DR
Vincerx Pharma just signed a material definitive agreement, filing an 8-K on Jan 31st.
AI Summary
Vincerx Pharma, Inc. filed an 8-K on February 6, 2025, reporting a material definitive agreement as of January 31, 2025. The filing also includes financial statements and exhibits. The company was formerly known as Vincera Pharma, Inc. and LifeSci Acquisition Corp.
Why It Matters
This 8-K filing indicates a significant new agreement for Vincerx Pharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Registrant
- Vincera Pharma, Inc. (company) — Former Company Name
- LifeSci Acquisition Corp. (company) — Former Company Name
- January 31, 2025 (date) — Date of earliest event reported
- February 6, 2025 (date) — Filing Date
FAQ
What is the nature of the material definitive agreement entered into by Vincerx Pharma, Inc. as of January 31, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into as of January 31, 2025.
When was Vincerx Pharma, Inc. formerly known as Vincera Pharma, Inc. and LifeSci Acquisition Corp.?
The company's name changed from Vincera Pharma, Inc. on December 23, 2020, and from LifeSci Acquisition Corp. on December 6, 2019.
What is the principal executive office address for Vincerx Pharma, Inc.?
The principal executive offices are located at 1825 S. Grant Street, San Mateo, California, 94402.
What is the telephone number for Vincerx Pharma, Inc.?
The registrant's telephone number, including area code, is (650) 800-6676.
What is the SIC code for Vincerx Pharma, Inc.?
The Standard Industrial Classification (SIC) code for Vincerx Pharma, Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 1,552 words · 6 min read · ~5 pages · Grade level 14 · Accepted 2025-02-06 16:05:14
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
- $13.66 m — d company upon the closing is less than $13.66 million, the exchange ratio would be adju
- $13.66 million — adjusted to meet this minimum value of $13.66 million. The Term Sheet also provided that inve
- $1,500,000 — stors determined by Oqory would provide $1,500,000 in interim financing to the Company, of
- $1,000,000 — erim financing to the Company, of which $1,000,000 was provided upon execution of the Term
- $14.16 million — combined company from $13.66 million to $14.16 million and waive the requirement for Oqory to
- $500,000 — ment for Oqory to provide the remaining $500,000 in interim financing. Item9.01 Finan
Filing Documents
- d875218d8k.htm (8-K) — 34KB
- d875218dex101.htm (EX-10.1) — 9KB
- 0001193125-25-021771.txt ( ) — 168KB
- vinc-20250131.xsd (EX-101.SCH) — 3KB
- vinc-20250131_lab.xml (EX-101.LAB) — 18KB
- vinc-20250131_pre.xml (EX-101.PRE) — 11KB
- d875218d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amendment #2 to Binding Term Sheet effective as of January 31, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "suggest," "seek," "intend," "plan," "goal," "potential," "on-target," "on track," "project," "estimate," "anticipate," or other comparable terms. All statements other than statements of historical facts included in this report are forward-looking statements. Forward-looking statements include, but are not limited to, the anticipated terms and conditions to entering into a definitive merger agreement. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside the control of Oqory and Vincerx. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the satisfactory completion of the parties' respective due diligence; the ability of the parties to successfully negotiate and enter into a definitive merger agreement and the actual terms thereof; termination of the Term Sheet; the parties' capital requirements, availability and sufficienc